FDA discontinue rare pediatric disease designation program despite increase in RPD approvals Read more
Session 14 of FOPE & PharmaState Academy’s PULSE Program explores investigations & CAPA under Revised Schedule M Read more
Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their primary endpoint Read more
FDA approves 127 innovator and biosimilar drugs in 2024, marks shift in pharma approval landscape Read more